达拉非尼联合曲美替尼显著改善黑色素瘤患者的整体生存率

Robert等人（Sun，）研究了这个问题。

www.synapsesocial.com/papers/69d6bfdbfca0359822aa8315 — DOI: https://doi.org/10.1056/nejmoa1412690

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma· 2014 · 1,860 citations
2. Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma· 2014 · 2,026 citations
3. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations· 2012 · 2,792 citations
4. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma· 2012 · 2,138 citations
5. COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF^V600E/Kmutation-positive cutaneous melanoma· 2014 · 69 citations